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Totally drug-resistant tuberculosis (TDR-TB): A debate on
global health communitiesFig. 1 – Round shaped TDR-TB bacilli; Ziehl–Neelsen staining
of digested sputum sample.
Fig. 2 – TDR-TB bacilli isolated from AFB culture-positive
samples; Ziehl–Neelsen staining.To date, totally drug-resistant tuberculosis (TDR-TB) has
been documented in four countries: Italy, Iran, India and
South Africa [1–4]. TDR-TB bacilli, which are sometimes re-
ferred to as extremely drug resistant TB (XXDR-TB), showed
in vitro resistance to all first- and second-line TB drugs
tested [1,2]. The term TDR-TB was proposed for multi-drug
resistant TB (MDR-TB) patients that remained smear and cul-
ture positive after 18 months of median treatment despite
second-line drug therapy [2]. In these patients, treatment
with Co-amoxiclav (625 mg/8 h) or Clarithromycin (1000 mg/
day1) along with a high dose of isoniazid (15 mg/kg1) had
no improvement and the majority of cases had expired with-
in the next two years of follow-up [2,5]. This means that
TDR-TB is even worse than MDR and extensively drug-resis-
tant TB (XDR-TB). The crisis may become more complicated
in countries where huge numbers of adults live with HIV.
Fortunately, the emergence of such deadly bacilli alerts the
TB experts worldwide [6,7]. But the World Health Organiza-
tion (WHO) declined to officially recognize TDR-TB on the
grounds that ‘‘lab tests done to confirm resistance to sec-
ond-line anti-TB drugs are unreliable and often not repro-
ducible [8].’’
With availability of TDR-TB isolates in the Iranian National
Reference TB Laboratory (NRL), the investigation at the cellu-
lar and the molecular levels was started. The culture suspen-
sion of TDR-TB bacilli were isolated and observed under
scanning, electron or atomic force microscopy. The results
showed morphological variation in shape, size, cell-division
and cell-wall content of TDR-TB bacilli [9–12]. Additionally,
the pili or tube-like structure (10–15%) was found on their cul-
ture isolates [11,13]. Even careful observation of positive
smear or culture specimen under light microscopy could re-
veal the round or oval shape TDR-TB bacilli (Figs. 1–3). All
these adaptations raise new debate on Koch bacilli. For exam-
ple, the rate of transmission and the time that round TDR-TB
bacilli can remain suspended in the air is not known. We even
do not know how the TB laboratory and clinical personals
should be protected. In addition, what will be the proposed
policy of isolating patients that carry such deadly bacilli? On
the other hand, the fate of round TDR-TB bacilli in the host
and how it provokes the immune responses has to be investi-
gated. These challenges underline the urgent need of discuss-
ing and reviewing the TDR-TB bacilli as ‘‘a new serve form of
tuberculosis.’’
Fig. 3 – Modified silver staining method; variable shape of
TDR-TB bacilli under light microscopy. The percentage of
round or oval shape cells are varied from 15% to 30% in
different patients.
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(Bedaquiline) by Johnson & Johnson Company had FDA ap-
proval [14]. Bedaquiline is the first medication exclusively
manufactured for MDR-TB patients [15]. The drug proved to
be effective in the first and second clinical trials, but the over-
all benefit remains unproven, especially when the manufac-
turer reported an increased risk of death (11%) in
comparison with the placebo treatment group [14]. Overall,
even if Bedaquiline proves to be effective in MDR patients, it
may take several years to reach the developing countries.
Therefore, as far as there is no cure for TDR-TB patients, it
is not exaggerating to say that the world is in danger of an
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